Avacta Group acquires Coris Bioconcept
Avacta Group has acquired Coris Bioconcept for £7.4 million and an extra £3 million payout based on future business performance.
If you are not happy with the results below please do another search
Avacta Group has acquired Coris Bioconcept for £7.4 million and an extra £3 million payout based on future business performance.
Integrative solutions at the speed of life
The Intelligent Analyzer
EASY. EFFICIENT. EXCEPTIONAL. Fully automated IIFT from primary sample to fi nal result
Patients with acute respiratory distress syndrome (ARDS) are particularly vulnerable to adverse effects of fluid overload. Plasma volume status (PVS), defined as the percentage deviation from ideal plasma volume, has emerged as a rapid, noninvasive method to assess volume status and prognosis:1
Simple. Efficient. Versatile.
Due to automated sample preparation, our new CLAM-2040 makes analysis easier and more efficient than ever before – perfect also for less experienced users.
HDL-c direct FS LDL-c direct FS
Scientists have taken an important step forward in predicting who will develop Type 1 diabetes months before symptoms appear.
A study of more than 22,000 people with multiple sclerosis has discovered the first genetic variant associated with faster disease progression, which can rob patients of their mobility and independence over time.